Allarity Therapeutics secures CLIA certification for in-house DRP testing lab

Allarity Therapeutics has obtained a CLIA Certificate of Registration for its in-house laboratory in Denmark. This certification enables the company to conduct DRP biomarker testing for U.S. registration trials, supporting potential pivotal studies for stenoparib. By shifting testing in-house, Allarity aims to reduce reliance on external labs, decrease turnaround times, and lower long-term development costs.

Allarity Therapeutics received a CLIA Certificate of Registration for its in-house laboratory in Denmark. * Certification clears the regulatory requirement to run DRP biomarker testing for U.S. registration trials, supporting a potential pivotal stenoparib study. * Move shifts testing in-house, cutting reliance on external labs, reducing turnaround times, lowering long-term development costs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here